News

Clinically robust and statistically significant results in primary and secondary endpoints for both 6- and 12-week cytisinicline treatment compared to placebo. Primary endpoints demonstrated 6-8x increased odds of smoking abstinence with cytisinicline compared to placebo. Cytisinicline was well tolerated with single-digit rates of adverse events observed. Management to host conference call today, April 27th at…

SEATTLE, Wash. and VANCOUVER, British Columbia, March 15, 2022 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a presentation on cytisinicline will be held during the Society for Research on Nicotine and Tobacco (SRNT) Annual…

SEATTLE, Wash and VANCOUVER, British Columbia, January 25, 2022 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it has initiated screening of ORCA-3, the confirmatory Phase 3 trial required for registrational approval of cytisinicline in…

Topline ORCA-2 Results expected in Q2 2022. SEATTLE, Wash and VANCOUVER, British Columbia, January 4, 2022 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the last study follow-up visit for the last subject enrolled…

Following the fifth and final DSMC review, committee has concluded no concerns with cytisinicline safety or Phase 3 trial conduct. SEATTLE, Wash and VANCOUVER, British Columbia, November 22, 2021 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction,…